Table 1.

Patient information.

			Gender		Tumour stage		Tumour grade		Tumours number		Recurrences
Group	n	Patients age (years)	M	F	Ta	T1	G1	G2-G3	< 5	≥ 5	< 3	≥ 3
1	12	37–76	10	2	6	6	3	9	1	11	3	9
2	13	36–83	10	3	7	6	3	10	10	3	12	1
3	16	39–72	3	13	5	11	0	16	7	9	7	9
4	10	40–82	0	10	7	2	2	8	3	7	10	0

Group 1 patients were given MMC (20 mg) combined with hyperthermia. Group 2 patients were given MMC alone at the same dose as group 1. Group 3 patients were given ICT (40 mg) combined with hyperthermia. Group 4 patients were given ICT alone at the same dosage as Group 3. Groups 1, 2 and 4 patients underwent the first treatment session within 21–40 days after a complete TUR of tumours, while group 3 patients were treated by leaving their tumour intact as a debulking approach for a bladder sparing purposes.